(VIANEWS) – LNA SANTE (LNA.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| LNA SANTE (LNA.PA) | €19.74 | 2.54% | 9.08% |
| EUROFINS SCIENT. (ERF.PA) | €55.96 | 2.16% | 9.12% |
| TUBIZE-FIN (TUB.BR) | €75.60 | 1.13% | 4.93% |
| VIRBAC (VIRP.PA) | €335.00 | 0.49% | 13.8% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. LNA SANTE (LNA.PA)
2.54% Forward Dividend Yield and 9.08% Return On Equity
LNA Santé SA engages in the management and operation of health establishments. The company operates retirement homes, medical and rehabilitation care, home hospital, surgery, mental health clinic, and health center. LNA Santé SA was founded in 1990 and is based in Vertou, France.
Earnings Per Share
As for profitability, LNA SANTE has a trailing twelve months EPS of €2.28.
PE Ratio
LNA SANTE has a trailing twelve months price to earnings ratio of 8.66. Meaning, the purchaser of the share is investing €8.66 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.08%.
More news about LNA SANTE.
2. EUROFINS SCIENT. (ERF.PA)
2.16% Forward Dividend Yield and 9.12% Return On Equity
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 130,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, and healthcare and cosmetics; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include product compliance and audit, testing, certifications and approvals, inspections, training courses, and digital media and cyber security for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, training and consulting; and testing for persistent organic pollutants, dioxins and organic contaminants, pesticides, mycotoxins, allergens, and pathogens and vitamins, as well as analyses for genetic modifications. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and technologies services. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.
Earnings Per Share
As for profitability, EUROFINS SCIENT. has a trailing twelve months EPS of €2.28.
PE Ratio
EUROFINS SCIENT. has a trailing twelve months price to earnings ratio of 24.54. Meaning, the purchaser of the share is investing €24.54 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.12%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Jul 4, 2023, the estimated forward annual dividend rate is 1 and the estimated forward annual dividend yield is 2.16%.
Volatility
EUROFINS SCIENT.’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.33%, a negative 0.23%, and a positive 1.15%.
EUROFINS SCIENT.’s highest amplitude of average volatility was 1.27% (last week), 1.00% (last month), and 1.15% (last quarter).
Moving Average
EUROFINS SCIENT.’s worth is higher than its 50-day moving average of €52.99 and under its 200-day moving average of €59.57.
More news about EUROFINS SCIENT..
3. TUBIZE-FIN (TUB.BR)
1.13% Forward Dividend Yield and 4.93% Return On Equity
Financière de Tubize SA operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium. The company is based in Brussels, Belgium.
Earnings Per Share
As for profitability, TUBIZE-FIN has a trailing twelve months EPS of €2.
PE Ratio
TUBIZE-FIN has a trailing twelve months price to earnings ratio of 37.8. Meaning, the purchaser of the share is investing €37.8 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.93%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, TUBIZE-FIN’s stock is considered to be overbought (>=80).
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on May 3, 2023, the estimated forward annual dividend rate is 0.86 and the estimated forward annual dividend yield is 1.13%.
More news about TUBIZE-FIN.
4. VIRBAC (VIRP.PA)
0.49% Forward Dividend Yield and 13.8% Return On Equity
Virbac SA manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.
Earnings Per Share
As for profitability, VIRBAC has a trailing twelve months EPS of €14.13.
PE Ratio
VIRBAC has a trailing twelve months price to earnings ratio of 23.71. Meaning, the purchaser of the share is investing €23.71 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.8%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 1%, now sitting on 1.21B for the twelve trailing months.
Moving Average
VIRBAC’s worth is way above its 50-day moving average of €262.38 and way above its 200-day moving average of €278.71.
Volatility
VIRBAC’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.30%, a negative 0.41%, and a positive 1.21%.
VIRBAC’s highest amplitude of average volatility was 0.30% (last week), 0.94% (last month), and 1.21% (last quarter).
Volume
Today’s last reported volume for VIRBAC is 719 which is 84.52% below its average volume of 4645.
More news about VIRBAC.
